GPR162 and Alzheimer disease: As in the discovery cohort, the corresponding size of distribution mode of GABRD+-carrying pTau217 and GPR162+-carrying pTau217 EVs were significantly smaller in AD vs NAD in the validation cohort (Fig. 5d, h).